Skip to content
OpenCapital
Get started

10x Genomics, Inc. TXG Licensing Arrangements

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%—

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AccruedRoyaltiesCurrent.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Questions, answered.

What is 10x Genomics, Inc.'s licensing arrangements?
10x Genomics, Inc. (TXG) reported licensing arrangements of $4.46M in Q1 2026.
How has 10x Genomics, Inc.'s licensing arrangements changed year-over-year?
10x Genomics, Inc.'s licensing arrangements increased by 6.4% year-over-year, from $4.19M to $4.46M.
What is the long-term trend for 10x Genomics, Inc.'s licensing arrangements?
Over 5 years (2020 to 2025), 10x Genomics, Inc.'s licensing arrangements has grown at a 9.5% compound annual growth rate (CAGR), from $3.16M to $4.97M.